Artal Group S.A. Bei Gene, Ltd. Call Options Transaction History

Artal Group S.A.

  • $214 Million
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$125.51 - $229.3 $6.28 Million - $11.5 Million
50,000 Added 100.0%
100,000 $22 Million
Q3 2022

Nov 14, 2022
BUY
$131.8 - $202.24 $6.59 Million - $10.1 Million
50,000 New
50,000 $6.74 Million
Q4 2018

Feb 11, 2019
BUY
$107.01 - $175.15 $21.4 Million - $35 Million
200,000 New
200,000 $28.1 Million

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email